By taking detailed measurements of blood and other biological samples, ISB scientists have shown they can identify markers for cancer years before diagnosis. This was the topic of a recent Research Roundtable presentation delivered by Dr. Andrew Magis, Director of Data Science in ISB’s Health Data Science Lab.
ISB researchers and their collaborators looked at the electronic health records of nearly 630,000 patients who were tested for SARS-CoV-2, and found stark disparities in COVID-19 outcomes — odds of infection, hospitalization, and in-hospital mortality — between White and non-White minority racial and ethnic groups.
ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.
By analyzing blood plasma samples taken at several time points, ISB researchers have identified specific proteins that persistently presented as outliers and signaled metastatic cancer well before patients were diagnosed. The findings were published in the journal Scientific Reports.
In a multi-institutional study of a highly infectious disease like COVID-19, paperless consent for study participants is critical. One component of the COVID-19 Immune Response Study is a recruitment website with an IRB-approved and HIPAA-compliant electronic consent platform for enrolling patients.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.